Oncology News | pharmaphorum

News

Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients w

News

Novartis' bid to extend Kymriah into earlier use hits a road...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

News

Third strike for GSK/Merck as bintrafusp alfa flubs again

GlaxoSmithKline's big gamble on Merck KGaA's bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial.

News

Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.

News

BMS gets FDA nod for Opdivo as first adjuvant bladder cancer...

Bristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer therapy, getting FDA approval for the drug for post-surgical treatment of invasive bladder canc

News

GSK claims broader 'tissue-agnostic' label for PD-1 drug Jem...

The FDA has approved GlaxoSmithKline's latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the drug.

Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Novartis' bid to extend Kymriah into earlier use hits a road...

Third strike for GSK/Merck as bintrafusp alfa flubs again

Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

BMS gets FDA nod for Opdivo as first adjuvant bladder cancer...

GSK claims broader 'tissue-agnostic' label for PD-1 drug Jem...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks